Literature DB >> 2971386

The pharmacokinetics of medroxyprogesterone acetate following two different loading dose schedules in advanced carcinoma of the breast.

P A Canney1, M Dowsett, T J Priestman.   

Abstract

A loading dose of MPA employing a regimen of 1,000 mg six hourly for 8 doses can achieve plateau levels above 100 ng ml-1 within the first 36 h of treatment, without any untoward toxicity. This raises the possibility of shortening the time to response for this agent. The additional factor of the time required to achieve adequate serum levels may explain the apparent contradictions between reports correlating response rates and dose and those correlating serum level and response.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2971386      PMCID: PMC2246490          DOI: 10.1038/bjc.1988.165

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  9 in total

1.  A radioimmunoassay for serum medroxyprogesterone acetate.

Authors:  K Shrimanker; B N Saxena; K Fotherby
Journal:  J Steroid Biochem       Date:  1978-04       Impact factor: 4.292

2.  Medroxyprogesterone acetate (MAP) relative bioavailability after single high-dose administration in cancer patients.

Authors:  F Pannuti; C M Camaggi; E Strocchi; M Giovannini; A R Di Marco; B Costanti
Journal:  Cancer Treat Rep       Date:  1982-12

3.  A possible new approach to the treatment of metastatic breast cancer: massive doses of medroxyprogesterone acetate.

Authors:  F Pannuti; A Martoni; G R Lenaz; E Piana; P Nanni
Journal:  Cancer Treat Rep       Date:  1978-04

4.  Randomized trial of low- versus high-dose medroxyprogesterone acetate in the induction treatment of postmenopausal patients with advanced breast cancer.

Authors:  F Cavalli; A Goldhirsch; F Jungi; G Martz; P Alberto
Journal:  J Clin Oncol       Date:  1984-05       Impact factor: 44.544

5.  Comparative pharmacokinetics of medroxyprogesterone acetate administered by oral and intramuscular routes.

Authors:  M Salimtschik; H T Mouridsen; J Loeber; E Johansson
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

6.  Pharmacokinetics of medroxyprogesterone acetate administered by oral and intramuscular route.

Authors:  J Løber; H T Mouridsen; M Salimtschik; E Johansson
Journal:  Acta Obstet Gynecol Scand Suppl       Date:  1981

7.  The pharmacokinetics of high-dose medroxyprogesterone acetate (MPA) in the therapy of advanced breast cancer.

Authors:  H C Blossey; H H Bartsch; D Kanne; J Koebberling; G A Nagel
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

8.  High dose medroxyprogesterone acetate (MPA) treatment in metastatic carcinoma of the breast: a dose-response evaluation.

Authors:  G R Cuna; A Calciati; M R Strada; C Bumma; L Campio
Journal:  Tumori       Date:  1978-04-30

9.  An evaluation of high-dose medroxyprogesterone acetate (MPA) therapy in women with advanced breast cancer.

Authors:  J R Johnson; T J Priestman; K Fotherby; K A Kelly; S G Priestman
Journal:  Br J Cancer       Date:  1984-09       Impact factor: 7.640

  9 in total
  2 in total

Review 1.  Hormonal Contraception and HIV-1 Acquisition: Biological Mechanisms.

Authors:  Janet P Hapgood; Charu Kaushic; Zdenek Hel
Journal:  Endocr Rev       Date:  2018-02-01       Impact factor: 19.871

2.  Adjuvant high-dose medroxyprogesterone acetate for early breast cancer: 13 years update in a multicentre randomized trial.

Authors:  C Focan; M Beauduin; E Salamon; J de Greve; G de Wasch; J P Lobelle; F Majois; A Tagnon; J Tytgat; S van Belle; R Vandervellen; A Vindevoghel
Journal:  Br J Cancer       Date:  2001-07-06       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.